XOMA Declares Quarterly Preferred Stock Dividends
March 21, 2023 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy
March 09, 2023 07:30 ET
|
XOMA Corporation
2022 was the first year with cash receipts from a commercial asset since becoming a royalty aggregator Ebopiprant royalty and milestone license acquisition gives XOMA the potential to earn up to $378...
XOMA to Present at 43rd Annual Cowen Health Care Conference
February 28, 2023 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today that Owen Hughes, Executive Chairman, and Brad Sitko, Chief...
XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 06, 2023 19:00 ET
|
XOMA Corporation
EMERYVILLE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”), the Biotech Royalty Aggregator, today announced the Company has granted Owen Hughes,...
New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy
January 04, 2023 07:30 ET
|
XOMA Corporation
Owen Hughes appointed Executive Chairman of the Board of Directors and Brad Sitko joins as Chief Investment Officer EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:...
XOMA Declares Quarterly Preferred Stock Dividends
December 22, 2022 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon
November 22, 2022 07:01 ET
|
XOMA Corporation
XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay Potential to earn $475...
XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events
November 03, 2022 07:30 ET
|
XOMA Corporation
Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). First five...
XOMA Declares Quarterly Preferred Stock Dividends
September 21, 2022 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends...
XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of...